Skip to main content
. Author manuscript; available in PMC: 2016 Jan 8.
Published in final edited form as: Nature. 2014 Dec 3;517(7533):209–213. doi: 10.1038/nature14034

Extended Data Figure 7. Celecoxib abrogates CK14+ cancer cell enrichment after GC chemotherapy in T24 and PDX-3 xenografts.

Extended Data Figure 7

a, In vivo treatment protocol recapitulating clinical regimen of one chemotherapy cycle in the presence or absence of celecoxib treatment. b, Immunofluorescence staining examining the percentage of CK14+ cancer cells in representative T24 xenograft tumours from various treatment groups. Scale bars, 1,000 μm. c, Immunohistochemical staining examining the percentage of CK14+ cancer cells in representative PDX-3 xenograft tumours from various treatment groups. Scale bars, 1,000 μm. Images in b and c are representative of n = 6 tumours analysed for each treatment group.